ZEJULA (Niraparib): Important update for the maintenance treatment in relapsed ovarian cancer in the second line or higher settings (2L+)

A Dear Healthcare Professional Letter has been issued by GlaxoSmithKline Pte Ltd to inform healthcare professionals of the updated overall survival (OS) data from the ENGOT-OV16/NOVA study, a Phase III trial which evaluated the efficacy and safety of niraparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. The OS results indicate a possible OS detriment to patients in the overall non-gBRCAmut cohort and to patients in the non-gBRCAmut/HRDpos subgroup who received niraparib maintenance in this setting, as compared to placebo. Healthcare professionals are advised to share the information in this letter with relevant healthcare personnel and patients under their supervision, so that patients can also make an informed decision regarding the use of niraparib in this setting. This recommendation does not apply to the first line ZEJULA indication. Please refer to the letter for details.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg ↗ (opens in new tab) and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.